Roles of leukemia inhibitory factor receptor in cancer
Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcrip...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2025-01, Vol.156 (2), p.262-273 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 273 |
|---|---|
| container_issue | 2 |
| container_start_page | 262 |
| container_title | International journal of cancer |
| container_volume | 156 |
| creator | Ma, Wei Yan, Haixu Ma, Haoyuan Xu, Zengyan Dai, Wei Wu, Yudan Zhang, Hongyan Li, Yanshu |
| description | Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy. |
| doi_str_mv | 10.1002/ijc.35157 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3105492342</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3105492342</sourcerecordid><originalsourceid>FETCH-LOGICAL-c203t-b351d2bf1e9795799a3bd3b6fd5f6e0f53a6b525982be4447cec3af82559e8093</originalsourceid><addsrcrecordid>eNpdkE1LAzEURYMotlYX_gEZcKOLqS95k5lmKcUvKAii6yHJvGDqdKYmnUX_valWF67ug3e4XA5j5xymHEDc-KWdouSyOmBjDqrKQXB5yMbpB3nFsRyxkxiXAJxLKI7ZCJWoFJdyzMqXvqWY9S5rafigldeZ79698Zs-bDOnbcoskKX17vBdZnVnKZyyI6fbSGf7nLC3-7vX-WO-eH54mt8ucisAN7lJqxphHCdVKVkppdE0aErXSFcSOIm6NFJINROGiqKoLFnUbiakVDQDhRN29dO7Dv3nQHFTr3y01La6o36INXKQhRJYiIRe_kOX_RC6tC5RCCUiICbq-oeyoY8xkKvXwa902NYc6p3MOsmsv2Um9mLfOJgVNX_krz38AiWTbVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130633033</pqid></control><display><type>article</type><title>Roles of leukemia inhibitory factor receptor in cancer</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Ma, Wei ; Yan, Haixu ; Ma, Haoyuan ; Xu, Zengyan ; Dai, Wei ; Wu, Yudan ; Zhang, Hongyan ; Li, Yanshu</creator><creatorcontrib>Ma, Wei ; Yan, Haixu ; Ma, Haoyuan ; Xu, Zengyan ; Dai, Wei ; Wu, Yudan ; Zhang, Hongyan ; Li, Yanshu</creatorcontrib><description>Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.</description><identifier>ISSN: 0020-7136</identifier><identifier>ISSN: 1097-0215</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.35157</identifier><identifier>PMID: 39279155</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; Apoptosis ; Cell activation ; Cell proliferation ; Cytokines ; Glycoprotein gp130 ; Humans ; Interleukin 6 ; Janus kinase ; Leukemia ; Leukemia inhibitory factor ; Leukemia Inhibitory Factor - metabolism ; Leukemia Inhibitory Factor Receptor alpha Subunit - metabolism ; Neoplasms - metabolism ; Neoplasms - pathology ; Receptors, OSM-LIF - metabolism ; Signal Transduction ; Tumor cells ; Tumorigenesis</subject><ispartof>International journal of cancer, 2025-01, Vol.156 (2), p.262-273</ispartof><rights>2024 UICC.</rights><rights>2025 UICC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c203t-b351d2bf1e9795799a3bd3b6fd5f6e0f53a6b525982be4447cec3af82559e8093</cites><orcidid>0009-0006-4272-8421 ; 0000-0003-4500-9247</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39279155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Yan, Haixu</creatorcontrib><creatorcontrib>Ma, Haoyuan</creatorcontrib><creatorcontrib>Xu, Zengyan</creatorcontrib><creatorcontrib>Dai, Wei</creatorcontrib><creatorcontrib>Wu, Yudan</creatorcontrib><creatorcontrib>Zhang, Hongyan</creatorcontrib><creatorcontrib>Li, Yanshu</creatorcontrib><title>Roles of leukemia inhibitory factor receptor in cancer</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Cell activation</subject><subject>Cell proliferation</subject><subject>Cytokines</subject><subject>Glycoprotein gp130</subject><subject>Humans</subject><subject>Interleukin 6</subject><subject>Janus kinase</subject><subject>Leukemia</subject><subject>Leukemia inhibitory factor</subject><subject>Leukemia Inhibitory Factor - metabolism</subject><subject>Leukemia Inhibitory Factor Receptor alpha Subunit - metabolism</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - pathology</subject><subject>Receptors, OSM-LIF - metabolism</subject><subject>Signal Transduction</subject><subject>Tumor cells</subject><subject>Tumorigenesis</subject><issn>0020-7136</issn><issn>1097-0215</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1LAzEURYMotlYX_gEZcKOLqS95k5lmKcUvKAii6yHJvGDqdKYmnUX_valWF67ug3e4XA5j5xymHEDc-KWdouSyOmBjDqrKQXB5yMbpB3nFsRyxkxiXAJxLKI7ZCJWoFJdyzMqXvqWY9S5rafigldeZ79698Zs-bDOnbcoskKX17vBdZnVnKZyyI6fbSGf7nLC3-7vX-WO-eH54mt8ucisAN7lJqxphHCdVKVkppdE0aErXSFcSOIm6NFJINROGiqKoLFnUbiakVDQDhRN29dO7Dv3nQHFTr3y01La6o36INXKQhRJYiIRe_kOX_RC6tC5RCCUiICbq-oeyoY8xkKvXwa902NYc6p3MOsmsv2Um9mLfOJgVNX_krz38AiWTbVQ</recordid><startdate>20250115</startdate><enddate>20250115</enddate><creator>Ma, Wei</creator><creator>Yan, Haixu</creator><creator>Ma, Haoyuan</creator><creator>Xu, Zengyan</creator><creator>Dai, Wei</creator><creator>Wu, Yudan</creator><creator>Zhang, Hongyan</creator><creator>Li, Yanshu</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0006-4272-8421</orcidid><orcidid>https://orcid.org/0000-0003-4500-9247</orcidid></search><sort><creationdate>20250115</creationdate><title>Roles of leukemia inhibitory factor receptor in cancer</title><author>Ma, Wei ; Yan, Haixu ; Ma, Haoyuan ; Xu, Zengyan ; Dai, Wei ; Wu, Yudan ; Zhang, Hongyan ; Li, Yanshu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c203t-b351d2bf1e9795799a3bd3b6fd5f6e0f53a6b525982be4447cec3af82559e8093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Cell activation</topic><topic>Cell proliferation</topic><topic>Cytokines</topic><topic>Glycoprotein gp130</topic><topic>Humans</topic><topic>Interleukin 6</topic><topic>Janus kinase</topic><topic>Leukemia</topic><topic>Leukemia inhibitory factor</topic><topic>Leukemia Inhibitory Factor - metabolism</topic><topic>Leukemia Inhibitory Factor Receptor alpha Subunit - metabolism</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - pathology</topic><topic>Receptors, OSM-LIF - metabolism</topic><topic>Signal Transduction</topic><topic>Tumor cells</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Wei</creatorcontrib><creatorcontrib>Yan, Haixu</creatorcontrib><creatorcontrib>Ma, Haoyuan</creatorcontrib><creatorcontrib>Xu, Zengyan</creatorcontrib><creatorcontrib>Dai, Wei</creatorcontrib><creatorcontrib>Wu, Yudan</creatorcontrib><creatorcontrib>Zhang, Hongyan</creatorcontrib><creatorcontrib>Li, Yanshu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Wei</au><au>Yan, Haixu</au><au>Ma, Haoyuan</au><au>Xu, Zengyan</au><au>Dai, Wei</au><au>Wu, Yudan</au><au>Zhang, Hongyan</au><au>Li, Yanshu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Roles of leukemia inhibitory factor receptor in cancer</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2025-01-15</date><risdate>2025</risdate><volume>156</volume><issue>2</issue><spage>262</spage><epage>273</epage><pages>262-273</pages><issn>0020-7136</issn><issn>1097-0215</issn><eissn>1097-0215</eissn><abstract>Leukemia inhibitory factor receptor (LIFR), in complex with glycoprotein 130 (gp130) as the receptor for leukemia inhibitory factor (LIF), can bind to a variety of cytokines and subsequently activate a variety of signaling pathways, including Janus kinase/signal transducer and activator of transcription 3. LIF, the most multifunctional cytokines of the interleukin-6 family acts as both a growth factor and a growth inhibitor in different types of tumors. LIF/LIFR signaling regulates a broad array of tumor-related processes including proliferation, apoptosis, migration, invasion. However, due to the activation of different signaling pathways, opposite regulatory effects are observed in certain tumor cells. Therefore, the role of LIFR in human cancers varies across different tumor and tissue, despite their recognized value in tumor treatment and prognosis observation is affirmed. Given its aberrant expression in numerous tumor cells and crucial regulatory function in tumorigenesis and progression, LIFR is considered as a promising targeted therapeutic agent. This review provides an overview of LIFR's initiating signaling pathway function as a cytokine receptor and summarize the current literature on the role of LIFR in cancer and its possible use in therapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39279155</pmid><doi>10.1002/ijc.35157</doi><tpages>12</tpages><orcidid>https://orcid.org/0009-0006-4272-8421</orcidid><orcidid>https://orcid.org/0000-0003-4500-9247</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2025-01, Vol.156 (2), p.262-273 |
| issn | 0020-7136 1097-0215 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3105492342 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Animals Apoptosis Cell activation Cell proliferation Cytokines Glycoprotein gp130 Humans Interleukin 6 Janus kinase Leukemia Leukemia inhibitory factor Leukemia Inhibitory Factor - metabolism Leukemia Inhibitory Factor Receptor alpha Subunit - metabolism Neoplasms - metabolism Neoplasms - pathology Receptors, OSM-LIF - metabolism Signal Transduction Tumor cells Tumorigenesis |
| title | Roles of leukemia inhibitory factor receptor in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Roles%20of%20leukemia%20inhibitory%20factor%20receptor%20in%20cancer&rft.jtitle=International%20journal%20of%20cancer&rft.au=Ma,%20Wei&rft.date=2025-01-15&rft.volume=156&rft.issue=2&rft.spage=262&rft.epage=273&rft.pages=262-273&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.35157&rft_dat=%3Cproquest_cross%3E3105492342%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130633033&rft_id=info:pmid/39279155&rfr_iscdi=true |